Richard Moore, BD DiagnosticsROCKVILLE AND BALTIMORE, MARYLAND, August 26, 2013 – BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today its selection of Richard Moore, M.D., Ph.D., as a new Entrepreneur-in-Residence (EIR) at the National Institutes of Health (NIH) Office of Technology Transfer (OTT). BHI and BD established this position in July 2013. Dr. Moore, an executive with decades of experience in diagnostics development and technology strategy, will help support the development of new start-up companies and product commercialization based upon innovative technologies selected via OTT license agreements.
“It is exciting for us to add Dr. Moore as our most recent addition to the EIR program,” said Todd Chappell, BHI Entrepreneur-in-Residence, NIH OTT, who heads up the EIR program for BHI. “There is a vast opportunity to commercialize research coming from NIH OTT, and Dr. Moore will be a complementary and very welcome resource to our team.”
Dr. Moore was selected for this role due to his experience as an executive in diagnostics development and technology commercialization strategy. He also has displayed a core passion for applying new technology to solve clinical problems from his years of in vitro diagnostic device development with emphasis in molecular assays for infectious disease, sepsis, and oncology. Dr. Moore previously served as the Chief Scientific Officer for OpGen, Inc. Prior to that, he spent 12 years at BD Diagnostics holding various positions, most recently as R&D Director, Systems Integration and Advanced Technology. Dr. Moore received his B.S. in Nuclear Engineering from the University of Maryland, College Park. He also received his M.D. and Ph.D. from University of Maryland, Baltimore.
“We’re extremely fortunate to have identified Dr. Moore for this new EIR role,” said Richard M. “Rick” Ivey, Worldwide Vice President Research & Development, BD Diagnostics – Diagnostic Systems, and a BHI Board member. “Dr. Moore and I previously worked together at BD, and I know he has the right background and approach to align technology assets in NIH OTT to the unmet needs in the clinical healthcare marketplace. Rich will be a true asset to this joint BHI/BD EIR program and to the NIH OTT.”
“This role is a natural next step in my career,” said Dr. Moore. “The potential for driving new start-ups and product commercialization from this program is tremendous, and I’m grateful to be a part of it.”
About BioHealth Innovation, Inc.
BioHealth Innovation, Inc., is a regional innovation intermediary focused on commercializing market-relevant bio-health innovations and increasing access to early-stage funding in Maryland.
About the NIH Office of Technology Transfer (NIH OTT)
OTT manages the patenting and licensing of a wide range of inventions made by scientists working for the NIH and FDA intramural research programs as mandated by the Federal Technology Transfer Act and related legislation. More information can be found at www.ott.nih.gov.
About the National Institutes of Health (NIH)
NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
# # #
Media contact:
Rich Bendis, President & CEO, 301-637-6439, rbendis@biohealthinnovation.org.